Related Experiment Video
Updated: Aug 22, 2026
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects
Gyula Tálosi1, Márta Katona, Katalin Rácz
1Department of Pediatrics, Albert Szent-Györgyi Medical and Pharmaceutical Centre, University of Szeged, Szeged, Hungary. talosigy@pedia.szote.u-szeged.hu
Insights
Prostaglandin E1 (PGE1) is vital for ductus-dependent congenital heart defects. While effective, monitor patients closely for side effects like fever, apnea, and electrolyte changes, especially in intensive care settings.
Area of Science:
- Pediatric Cardiology
- Neonatology
- Pharmacology
Background:
- Prostaglandin E1 (PGE1) is a critical intervention for ductus-dependent congenital heart defects.
- Understanding PGE1's indications, side effects, and impact on serum electrolytes is crucial for optimizing patient care.
Purpose of the Study:
- To analyze the indications for PGE1 therapy in neonates and infants.
- To document the early side effects of PGE1 treatment.
- To investigate potential changes in serum electrolyte levels during PGE1 therapy.
Main Methods:
- Retrospective analysis of 49 patients treated with PGE1 over five years.
- Documentation of indications for PGE1 administration.
- Recording of observed side effects and monitoring of serum electrolytes (sodium, potassium, chloride, pH).
Main Results:
- PGE1 was indicated for various ductus-dependent congenital heart defects, including systemic and pulmonary circulation issues, transposition of the great arteries, and persistent pulmonary hypertension.
- Common side effects included fever (27/49) and apnea (15/49). One case of intraventricular hemorrhage was noted.
- Mild decreases in sodium, potassium, and chloride levels, along with a trend towards metabolic alkalosis, were observed after one day and one week of treatment.
Conclusions:
- PGE1 is essential for managing ductus-dependent congenital heart defects but requires careful monitoring in intensive care due to potential side effects.
- While electrolyte levels may decrease slightly, supplementation is generally not necessary for short-term therapy.
- Continuous monitoring is recommended to manage adverse events effectively.
Abstract:
Prostaglandin E1 (PGE1) treatment can be life saving in patients suffering from ductus dependent congenital heart defect. We analyzed the indications and side-effects of PGE1 therapy over a five-year period. The purpose of the study was also to examine whether a change in serum electrolyte levels could be detected. Forty-nine patients were treated with PGE1 during this period. PGE1 treatment was indicated by ductus dependent systemic circulation in 16 cases, ductus dependent pulmonary circulation in 17 cases, transposition of the great arteries in 13 cases and pulmonary hypertension (persistent fetal circulation) in three cases. As early side-effects of the treatment, fever occurred in 27/49 cases while apnoea was observed in 15 patients. In a one-week-old neonate with coarctation of the aorta grade III intraventricular hemorrhage developed. A mild decrease of sodium, potassium and chloride levels and a slight shift of pH levels toward metabolic alkalosis could be detected after one day and one week of PGE1 treatment. Because of these side-effects of PGE1 patients should be monitored in an intensive care unit. According to our observations electrolyte levels may exhibit a slight decrease; however, in the case of a short-term therapy extra salt supplementation is not necessary.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...